Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

AstraZeneca · Phase 3 · Completed · Enrollment 119

NCT02635386

Y axis: Change in body weight from baseline, %

105004812162024Exenatide once weekly (EQW ), week 24, 3.8%Dapagliflozin (DAPA), week 24, 1.5%EQW plus DAPA, week 24, 6.9%Dapagliflozin plus Glucophage (MET ER), week 24, 1.7%Phentermine /Topiramate (PHEN/ TPM) ER, week 24, 8.1%

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Exenatide once weekly (EQW ), one timepoint
  • Dapagliflozin (DAPA), one timepoint
  • EQW plus DAPA, one timepoint
  • Dapagliflozin plus Glucophage (MET ER), one timepoint
  • Phentermine /Topiramate (PHEN/ TPM) ER, one timepoint
  • Exenatide once weekly (EQW ): week 24 3.8%
  • Dapagliflozin (DAPA): week 24 1.5%
  • EQW plus DAPA: week 24 6.9%
  • Dapagliflozin plus Glucophage (MET ER): week 24 1.7%
  • Phentermine /Topiramate (PHEN/ TPM) ER: week 24 8.1%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.